The effect of Hepatitis C Virus infection on cardiovascular complications in end stage kidney disease patients on regular hemodialysis
Keywords:
Hepatitis C, Viremia, End stage renal disease, Cardiovascular complicationAbstract
Introduction: Cardiovascular complications are the most important cause of mortality in patients with ESKD, such as coronary artery disease, left ventricular hypertrophy, heart failure and arrhythmia. Other well-known risk factors, such as diabetes mellitus, hypertension and dyslipidemia are prevalent in ESKD, yet they are not sufficient enough to explain the high prevalence of cardiovascular mortality, hence searching for other hidden risk factors to explain this high prevalence is of an utmost importance. The aim of this study was to identify the exact mechanisms connecting HCV infection, chronic liver disease, and atherogenesis.
Methods: This case control study was done on 80 patients with chronic renal failure undergoing haemodialysis at Sheikh Zayed Specialized Hospital in Giza, Egypt in 2016. The participants were divided into four groups: a control group with HCV negative by PCR (20 patients), and three HCV Positive groups according to viral load by PCR: low, moderate and high viremia. Inclusion criteria were normal serum calcium (8.5-10.5 mg/dL), phosphorus ≤5mg/dL, PTH≤250 pg/ml, Hb 10-12 g/dL, and duration of dialysis less than two years. Data were analyzed using Chi square, t-test, Mann-Whitney U test, ANOVA, and Spearman rank correlation coefficient.
Results: The study showed significant increase in LVM index in hemodialysis patients with high and moderate viremia compared to low viremia (p<0.001) and to control group (p<0.001). Also, significant increase in end diastolic diameter in high and moderate viremia (p<0.001), significant difference in end systolic diameter in the high viremia group (p<0.001), significant increase in the interventricular septal thickness (p<0.002) and posterior wall thickness (p<0.002) among moderate viremia were determined.
Conclusion: HCV has a significant effect on the development of cardiovascular diseases in the general population, and in renal disease patients on the structural level.
References
Ferri C, Sebastiani M, Giuggioli D, Colaci M, Fallahi P, Piluso A, et al. Hepatitis C virus syndrome: A
constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and
cancer. World J Hepatol. 2015; 7(3): 327. doi: 10.4254/wjh.v7.i3.327. PMID: 25848462, PMCID:
PMC4381161.
Fabrizi F. Hepatitis C Virus Infection and Dialysis: 2012 Update. International Scholarly Research Notices.
doi: 10.5402/2013/159760.
Oyake N, Shimada T, Murakami Y, Ishibashi Y, Satoh H, Suzuki K, et al. Hepatitis c virus infection as a
risk factor for increased aortic stiffness and cardiovascular events in dialysis patients. J Nephrol. 2008;
(3): 345-53. PMID: 18587722.
Younossi ZM, Stepanova M, Nader F, Younossi Z, Elsheikh E. Associations of Chronic Hepatitis C With
Metabolic and Cardiac outcomes. Aliment Pharmacol Ther. 2013; 37(6): 647-52. doi: 10.1111/apt.12234.
PMID: 23384408.
Adinolfi LE, Zampino R, Restivo L, Lonardo A, Guerrera B, Marrone A, et al.. Chronic hepatitis C virus
infection and atherosclerosis: Clinical impact and mechanisms. World J Gastroenterol. 2014 Apr
;20(13):3410-7. doi: 10.3748/wjg.v20.i13.3410. PMID: 24707124, PMCID: PMC3974508
Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic
validation of the method. Circulation. 1977; 55: 613-8. PMID: 138494.
Caliskan Y, Oflaz H, Pusuroglu H, Boz H, Yazici H, Tamer S, et al. Hepatitis C virus infection in
hemodialysis patients is not associated with insulin resistance, inflammation and atherosclerosis. Clin
Nephrol. 2009; 71(2): 147-57. PMID: 19203507.
Omura T, Yoshiyama M, Hayashi T, Nishiguchi S, Kaito M, Horiike S, et al. Core protein of hepatitis C
virus induces cardiomyopathy. Circ Res. 2005; 96: 148–50. doi: 10.1161/01.RES.0000154263.70223.13.
PMID: 15618537.
De Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability
of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict
cardiovascular risk. J Am Coll Cardiol. 1995; 25: 1056-62. doi: 10.1016/0735-1097(94)00540-7. PMID:
Matsumori A. Hepatitis C Virus Infection and Cardiomyopathies. Circulation Research. 2005; 96(2): 144- 7. doi: 10.1161/01.RES.0000156077.54903.67.
Petta S, Torres D, Fazio G, Cammà C, Cabibi D, Di Marco V, et al. Carotid Atherosclerosis and Chronic
Hepatitis C: Prospective Study of Risk Associations. Hepatology. 2012; 55(5): 1317-23. doi:
1002/hep.25508. PMID: 22135089.
Roed T, Kristoffersen US, Knudsen A, Wiinberg N, Lebech AM, Almdal T, et al. Increased prevalence of
coronary artery disease risk markers in patients with chronic hepatitis C--a cross-sectional study. Vasc
Health Risk Manag. 2014; 10: 55-62. doi: 10.2147/VHRM.S53557. PMID: 24482574, PMCID:
PMC3905100.
Karbasi Afshar R, Adibi P, Khedmat H, Jalali AR. How Hepatitis C Virus Infection Contributes to
Cardiovascular Disease: A Systematic Review. International Journal of Travel Medicine & Global Health.
; 1(2).
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
